Affiliation:
1. IMIBIC: Instituto Maimonides de Investigacion Biomedica de Cordoba
2. University of Milan: Universita degli Studi di Milano
3. IARC: International Agency for Research on Cancer
4. University of Cordoba: Universidad de Cordoba
Abstract
Abstract
Background
Lung neuroendocrine neoplasms (LungNENs) comprise a heterogeneous group of tumors ranging from indolent lesions with good prognosis to highly aggressive cancers. Carcinoids are the rarest LungNENs, display low to intermediate malignancy and may be surgically managed, but show resistance to radiotherapy/chemotherapy in case of metastasis. Molecular profiling is providing new information to understand lung carcinoids, but its clinical value is still limited. Altered alternative splicing is emerging as a novel cancer hallmark unveiling a highly informative layer.
Methods
We primarily examined the status of the splicing machinery in lung carcinoids, by assessing the expression profile of the core spliceosome components and selected splicing factors in a cohort of 25 carcinoids using a microfluidic array. Results were validated in an external set of 51 samples. Dysregulation of splicing variants was further explored in silico in a separate set of 18 atypical carcinoids. Selected altered factors were tested by immunohistochemistry, their associations with clinical features were assessed and their putative functional roles were evaluated in vitro in two lung carcinoid-derived cell lines.
Results
The expression profile of the splicing machinery was profoundly dysregulated. Clustering and classification analyses highlighted five splicing factors: NOVA1, SRSF1, SRSF10, SRSF9 and PRPF8. Anatomopathological analysis showed protein differences in the presence of NOVA1, PRPF8 and SRSF10 in tumor versus non-tumor tissue. Expression levels of each of these factors were differentially related to distinct number and profiles of splicing events, and were associated to both common and disparate functional pathways. Accordingly, modulating the expression of NOVA1, PRPF8 and SRSF10 in vitropredictably influenced cell proliferation and colony formation, supporting their functional relevance and potential as actionable targets.
Conclusions
These results provide primary evidence for dysregulation of the splicing machinery in lung carcinoids and suggest a plausible functional role and therapeutic targetability of NOVA1, PRPF8 and SRSF10.
Publisher
Research Square Platform LLC
Reference60 articles.
1. Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2022 Mar;17(3):362–87.
2. MEN1 gene mutation and reduced expression are associated with poor prognosis in pulmonary carcinoids;Swarts DRA;J Clin Endocrinol Metab
3. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D;Simbolo M;J Pathol
4. Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretić L, Seidal D et al. Frequent mutations in chromatin-remodeling genes in pulmonary carcinoids. Nat Commun 2014 Mar 27;5:3518.
5. An exploration of pathways involved in lung carcinoid progression using gene expression profiling;Swarts DRA;Carcinogenesis